BioSpace News Archive

On track to initiate Phase 3 trials within the EMERGENT program, the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia, by the end of 2020

ViewRay, Inc. announced that Kaohsiung Medical University Chung-Ho Memorial Hospital in Kaohsiung City, Taiwan has begun patient treatments with the MRIdian® MR-Guided Radiation Therapy System, a cutting-edge device that delivers personalized cancer care by combining the latest innovations in precision radiation delivery with ground-breaking MR-guidance.

CVS Health Corporation announced operating results for the three months ended June 30, 2020.

Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2020 and provided a business update.

BeiGene, Ltd. announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology Virtual Congress, taking place on September 18-22, 2020.

First Patient Receives New Sacral Neuromodulation Device Implant at Cleveland Clinic

Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy.

Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102.

Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter